Date: 2017-01-30
Type of information: R&D agreement
Compound:
Company: Novo Nordisk (Denmark) Oxford University's Medical Sciences Division (UK)
Therapeutic area: Metabolic diseases
Type agreement: R&D collaboration
Action mechanism:
Disease: type 2 diabetes
Details: * On January 30, 2017, University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. The collaboration will actively seek to encourage cross-fertilisation of ideas between academic researchers from the University of Oxford and researchers employed by Novo Nordisk with funds to sponsor the collaborative research. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford. The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers, based in an Oxford University research centre. The total investment from Novo Nordisk is expected to be around 1 billion Danish kroner (115 million British pounds) over a period of 10 years. The centre will focus on innovation within early stage research that has potential to substantially impact future treatment of type 2 diabetes and its complications. James D. Johnson, Professor, PhD, has been appointed head of the Novo Nordisk Research Centre Oxford. He is a world-renowned researcher in the fundamental biology of pancreatic islets, insulin action, diabetes and related conditions. Dr Johnson is currently Professor at the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia.
Financial terms:
Latest news:
